

This article was downloaded by:

On: 27 January 2011

Access details: *Access Details: Free Access*

Publisher *Taylor & Francis*

Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: Mortimer House, 37-41 Mortimer Street, London W1T 3JH, UK



Nucleosides, Nucleotides and Nucleic Acids

Publication details, including instructions for authors and subscription information:

<http://www.informaworld.com/smpp/title~content=t713597286>

Role of Adenosine Kinase in the Biological (Antiviral and Anticellular) Activities of Adenosine Analogues

Marina Cools^a; Erik De Clercq^a; John C. Drach^b

^a Rega Institute for Medical Research, Katholieke Universiteit Leuven, Leuven, Belgium ^b Department of Oral Biology, School of Dentistry, The University of Michigan, Ann Arbor, Michigan, U.S.A.

To cite this Article Cools, Marina , De Clercq, Erik and Drach, John C.(1987) 'Role of Adenosine Kinase in the Biological (Antiviral and Anticellular) Activities of Adenosine Analogues', *Nucleosides, Nucleotides and Nucleic Acids*, 6: 1, 423 — 424

To link to this Article: DOI: 10.1080/07328318708056245

URL: <http://dx.doi.org/10.1080/07328318708056245>

PLEASE SCROLL DOWN FOR ARTICLE

Full terms and conditions of use: <http://www.informaworld.com/terms-and-conditions-of-access.pdf>

This article may be used for research, teaching and private study purposes. Any substantial or systematic reproduction, re-distribution, re-selling, loan or sub-licensing, systematic supply or distribution in any form to anyone is expressly forbidden.

The publisher does not give any warranty express or implied or make any representation that the contents will be complete or accurate or up to date. The accuracy of any instructions, formulae and drug doses should be independently verified with primary sources. The publisher shall not be liable for any loss, actions, claims, proceedings, demand or costs or damages whatsoever or howsoever caused arising directly or indirectly in connection with or arising out of the use of this material.

ROLE OF ADENOSINE KINASE IN THE BIOLOGICAL (ANTIVIRAL AND ANTICELLULAR)
ACTIVITIES OF ADENOSINE ANALOGUES

Marina Cools^{1*}, Erik De Clercq¹ and John C. Drach²

¹Rega Institute for Medical Research, Katholieke Universiteit Leuven,
B-3000 Leuven, Belgium

²Department of Oral Biology, School of Dentistry,
The University of Michigan, Ann Arbor, Michigan 48109, U.S.A.

Abstract. A paired adenosine kinase-positive/adenosine kinase-negative cell system is proposed to distinguish those adenosine analogues that need to be phosphorylated to exert their biological effects from those that are mainly targeted at S-adenosyl-L-homocysteine hydrolase.

To assess the role of adenosine kinase in the biological properties of adenosine analogues, the latter were evaluated for their antiviral and anti-cellular activity in a paired cell system existing of adenosine kinase-positive (AK⁺) wild type B-mix K-44/6 (Rous sarcoma virus-transformed) rat cells and an adenosine kinase-negative (AK⁻) mutant cell line (clone D-4) derived thereof; both cell lines being devoid of adenosine deaminase activity¹.

Materials and Methods

Inhibition of virus-induced cytopathogenicity in vitro. The procedure for measuring inhibition of virus-induced cytopathogenicity has been described previously². The antiviral activity was expressed as MIC₅₀ or minimum inhibitory concentration required to reduce viral cytopathogenicity by 50 %.

Cytotoxicity. Cytotoxicity measurements were based on two parameters: (i) alteration of normal cell morphology and (ii) inhibition of cell growth. To evaluate cell morphology, confluent cell cultures which had not been infected, but were treated with various concentrations of the test compounds were incubated in parallel with the virus-infected cell cultures and examined microscopically at the same time as viral cytopathogenicity was recorded for the virus-infected cell cultures. A disruption of the cell monolayer was considered as evidence for cytotoxicity. To measure inhibition of cell growth, the cells were seeded in microtest plates (at 6,000 cells/well) in Eagle's minimum essential medium containing 10 % horse serum, and

4 h later various concentrations of the test compounds were added. The cells were then allowed to proliferate during 72 h at 37° C in a humidified, CO₂-controlled atmosphere. The growth of the cells was linear during this period. At the end of the incubation period, cells were trypsinized and enumerated in a Coulter counter. Cell growth-inhibiting activity was expressed as ID₅₀, that is the dose required to reduce the number of living cells by 50 %.

Results

According to their ID₅₀ for cell growth and MIC₅₀ for virus replication, the adenosine analogues could be clearly divided in two classes: I, those compounds that inhibited the growth of AK⁺ cells at a 150- to 1500-fold lower ID₅₀ than the growth of AK⁻ cells; these compounds also inhibited virus replication in AK⁺ cells at a 1000- to 10,000-fold lower MIC₅₀ than virus replication in AK⁻ cells; and, II, those compounds that were only slightly (5- to 15-fold) more inhibitory to AK⁺ than AK⁻ cell growth and only 1- to 50-fold more antivirally active in AK⁺ cells than in AK⁻ cells. To class I compounds belong tubercidin, toyocamycin, sangivamycin, β-xylo-adenosine and α-lyxoadenosine, and to class II compounds belong 3-deazaadenosine (c³Ado), carbocyclic 3-deazaadenosine (C-c³Ado), (S)-9-(2,3-dihydroxypropyl)adenine [(S)-DHPA], (RS)-3-adenin-9-yl-2-hydroxypropanoic acid [(RS)-AHPA] (isobutyl ester) and neplanocin A.

Discussion

Apparently, the antiviral and anticellular activity of the class I compounds critically depends on phosphorylation by the host cell adenosine kinase, which means that these compounds are biologically active primarily as their phosphorylated products. Such phosphorylation seems to be of lesser or no importance for the class II compounds, which have all been recognized previously as potent inhibitors of S-adenosyl-L-homocysteine (SAH) hydrolase^{3,4}. The present findings with the paired AK⁻/AK⁺ cell system are consistent with an action of the class II compounds targeted at SAH hydrolase.

REFERENCES

- (1) C. Shipman Jr., S.-L. Tong, S.H. Smith, N.B. Katlama, and J.C. Drach, *Antimicrob. Agents Chemother.* 24, 947 (1983).
- (2) E. De Clercq, J. Descamps, P. De Somer, and A. Holý, *Science* 200, 563 (1978).
- (3) P.K. Chiang, H.H. Richards, and G.L. Cantoni, *Mol. Pharmacol.* 13, 939 (1977).
- (4) E. De Clercq, and M. Cools, *Biochem. Biophys. Res. Commun.* 129, 306 (1985).